Abstract
Current studies of NAAG Peptidase Inhibitors show their potential for neuroprotection of dopaminergic cells and result in a reduction in Glutamate excitotoxicity. These results reveal that NAAG Peptidase Inhibitors could assist clinicians in understanding the pathophysiology of PD leading to a more effective treatment of patients’ symptoms. They underscored some of the most historical attempts in experimental therapeutics of PD in the past decade. The futility of some of the studies should be examined in the context of the current science as discussed in our paper. A deeper understanding of NAAG Peptidase inhibition could potentially accelerate early stages of PD interventions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
